Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...

CVS Health is the first major player to end some of its Humira coverage in order to make way for biosimilars. (CVS) This year, CVS Health plans to employ the classic "out with the old, in with the new ...

FILE - Packaging for AbbVie's drug, Humira. Humira-referenced biosimilars have been launched this year, but have thus far gained very little traction. (AP Photo/David J. Phillip, File) The blockbuster ...

A not-insignificant part of Humira’s financial success is due to the fact that it enjoys a monopoly in the US. This has allowed its maker, AbbVie, to name its price for the drug, which is prescribed ...

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie 's Humira are plummeting as the once-top-selling drug fights ...

Ten biosimilars have hit the market since the start of 2023. Still, AbbVie's branded drug holds the majority of the market. (iStock / Getty Images Plus / SvetaZi) Even through an onslaught of ...